🧬 Solid Tumor CAR-T in China — Satri-cel, $89K–$170K, and the World's First Solid-Tumor CAR-T Approval (2026 Guide)

🧬 What CAR-T Is and Why China Leads

Chimeric Antigen Receptor T-cell (CAR-T) therapy is a personalized cellular immunotherapy. A patient's own T cells are collected by apheresis, genetically modified in a manufacturing facility to express a chimeric receptor that recognizes a tumor antigen, expanded, and reinfused. After a lymphodepleting chemotherapy conditioning regimen, the engineered T cells expand in vivo, recognize the tumor antigen, and kill antigen-bearing cancer cells.

CAR-T has produced durable remissions in B-cell hematologic malignancies (leukemia, lymphoma, multiple myeloma). The unsolved challenge has always been solid tumors — the tumor microenvironment suppresses T-cell function, target antigens are often shared with normal tissues, and trafficking to solid tumor beds is harder. June 2026's satri-cel approval is the first regulatory acknowledgment that the field has crossed the solid-tumor threshold for at least one indication.

Why China Leads

• Volume and velocity: 7 approved CAR-T products as of mid-2026 — more than the US (6) and the EU (5). Chinese developers move from IND to first-in-human faster than Western peers, in part because of regulatory structure, in part because of dense patient access at top oncology centers.
• Manufacturing scale: China has multiple commercial-grade viral vector and CAR-T cell manufacturing facilities, allowing the per-patient cost to be 70-85% lower than US equivalents while maintaining cGMP quality.
• Target diversity: Chinese developers have pushed beyond the CD19/BCMA hematologic space into Claudin18.2 (gastric/GEJ), GPC3 (hepatocellular), mesothelin, claudin6, EGFRvIII, and others — some of which are still in US/EU Phase 1.
• Solid-tumor leadership: The 2016 first-in-human CRISPR-edited T-cell trial (PD-1 knock-out, lung cancer, Sichuan University) was a Chinese first. The June 2026 satri-cel approval is the next landmark.

For a broader look at Chinese biotech's role in CAR-T, see China as a CAR-T Global Destination, CAR-T Cost in China 2026, and Solid Tumor CAR-T Breakthrough.

🏆 Satri-cel: The June 2026 Solid-Tumor Milestone

Satricabtagene autoleucel (satri-cel) is an autologous CAR-T product whose chimeric receptor targets Claudin18.2 — a tight-junction protein expressed in normal gastric epithelium and re-expressed at high levels in a large fraction of gastric and gastroesophageal junction (GEJ) adenocarcinomas.

The product was developed by CARsgen Therapeutics, a Shanghai-based biotech that ran the clinical program across multiple Chinese centers. The pivotal Phase 2 trial, reported in The Lancet, randomized Claudin18.2-positive, previously treated advanced gastric/GEJ cancer patients. Median overall survival in the satri-cel arm was 3.25 months vs 1.77 months in the control arm — a meaningful survival signal in heavily pretreated disease, and the basis for NMPA approval.

Approval was announced by China's National Medical Products Administration (NMPA) in June 2026 for adult patients with Claudin18.2-positive, advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed on at least two prior lines of systemic therapy. Claudin18.2 positivity must be confirmed by IHC on tumor tissue (typically ≥2+ in ≥40% of tumor cells, per the trial's eligibility definition; the hospital pathology team will confirm current criteria before scheduling).

Why This Approval Matters

• First solid tumor: No CAR-T product had previously been approved for a solid tumor indication anywhere in the world. Satri-cel is the first.
• New target class: Claudin18.2 joins CD19 and BCMA as commercially validated CAR-T targets. Other Claudin18.2 programs (including bispecific antibodies) are now read against this benchmark.
• Adjacent targets in development: GPC3 CAR-T for hepatocellular carcinoma (e.g., Oricell's program) is in NMPA Phase 2. Mesothelin, Claudin6, and EGFRvIII CAR-T programs are in early-phase trials. The satri-cel approval sets the regulatory and clinical template.

For the original news coverage, see CARsgen Satri-cel — World's First Solid Tumor CAR-T (June 2026).

💉 Other Approved CAR-T Therapies in China (as of mid-2026)

China's seven approved CAR-T products span hematologic malignancies and (with satri-cel) one solid-tumor indication. Two of the most-traveled-for products are:

Axicabtagene Ciloleucel (Yescarta-class) for B-cell Lymphoma

An anti-CD19 CAR-T used in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell lymphomas. Multiple Chinese manufacturers produce CD19-directed CAR-T products with comparable efficacy to the original Kite/Gilead product, at substantially lower cost.

Relmacabtagene Autoleucel for B-cell Lymphoma

Another anti-CD19 CAR-T, developed and approved in China for relapsed/refractory B-cell lymphoma. Frequently used in international patients from Southeast Asia, the Middle East, and CIS countries who travel to Jiahui Health and other Shanghai centers.

Other approved products in the Chinese portfolio include BCMA-directed CAR-T for multiple myeloma and additional CD19 products. The full portfolio is the deepest of any single country, and is one reason cancer centers in Shanghai, Beijing, and Wuhan have become regional CAR-T hubs for international patients.

For an adjacent solid-tumor trial angle, see Oricell GPC3 CAR-T for HCC — NMPA Phase 2 Clearance.

🏥 Top Hospitals for CAR-T Therapy in China (2026)

CAR-T delivery requires apheresis, cell product handling, lymphodepleting conditioning, infusion, and a 2-4 week monitoring period for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The hospitals below have the highest volume, the strongest international patient infrastructure, and the most active clinical trial programs.

Additional strong CAR-T centers include Tongji Hospital (Wuhan), Henan Cancer Hospital, the First Affiliated Hospital of Zhejiang University, and West China Hospital (Sichuan University). For international patients who need to access a specific trial, the right center is usually defined by which trial sites are open — not just hospital ranking. For more, see Shanghai hospitals and Beijing hospitals.

💰 Cost: CAR-T in China vs the US vs the EU (2026)

Cost is the single biggest reason patients travel to China for CAR-T. Approved products in China are priced at roughly 15-30% of US list prices for the same class of therapy. For satri-cel specifically, the publicly reported range is $89,000-170,000 USD for the full course including apheresis, manufacturing, lymphodepletion, infusion, and the post-infusion monitoring period.

CAR-T Cost Comparison (USD, full course)

Product / Class	China	United States	European Union	Savings
Satri-cel (Claudin18.2, gastric/GEJ)	$89,000-170,000	Not yet approved	Not yet approved	—
Anti-CD19 CAR-T (DLBCL / B-cell lymphoma)	$80,000-160,000	$500,000-700,000+	$300,000-500,000	70-85%
Anti-BCMA CAR-T (multiple myeloma)	$100,000-180,000	$500,000-700,000+	$300,000-450,000	70-85%
Adjacent inpatient monitoring (2-4 weeks)	Included	Often billed separately	Often billed separately	—

The Chinese pricing reflects lower manufacturing labor and facility cost, locally produced viral vectors, and competition among multiple Chinese CD19/BCMA developers. The list price is the all-in quote at most top centers; confirm whether the apheresis, lymphodepleting chemo, ICU standby for CRS, and 2-4 week post-infusion monitoring are included.

🛂 How International Patients Access CAR-T in China

Route 1 — Commercial (Approved Product)

For satri-cel (Claudin18.2+ gastric/GEJ cancer after ≥2 prior lines) and approved hematologic CAR-T products, the path is:

1. Confirm target antigen: Send pathology report confirming Claudin18.2 (IHC), CD19, or BCMA status, plus recent imaging, labs, and treatment history.
2. Hospital case review: The hematology/oncology team reviews candidacy, confirms eligibility (performance status, organ function, no active infection/CNS disease), and proposes a treatment date.
3. Apheresis visit (1 week): Patient travels to China for T-cell collection. Cells are shipped to the manufacturing facility (CARsgen for satri-cel; other facilities for hematologic products). Manufacturing time: 2-4 weeks.
4. Lymphodepletion + infusion (3-4 weeks inpatient): Patient returns for conditioning chemotherapy, CAR-T infusion, and the post-infusion monitoring period (typically 14-21 days inpatient for CRS/ICANS surveillance).
5. Follow-up: Response assessment at 1, 3, 6, and 12 months post-infusion. Hospitals coordinate via telemedicine and arrange local oncologist handoff in the patient's home country.

Route 2 — Clinical Trial

For newer solid-tumor targets (GPC3, mesothelin, Claudin6, EGFRvIII, others) and next-generation constructs, trial access is often the only path. Top Chinese centers run dozens of active CAR-T trials. The China Hospital Guide editorial team can help match your target antigen to active trial sites.

What the Hospital Provides

• M-visa invitation letter (typically 3-6 month stay, extendable)
• English-speaking hematology/oncology coordinator and translator services in other major languages
• Apheresis, cell handling, and infusion under one roof
• ICU capability for severe CRS/ICANS — a non-negotiable for safe CAR-T delivery
• Discharge documentation, imaging, and a structured letter to the home oncologist

For the broader planning workflow, see How to Prepare for Medical Travel to China and Medical Guide: Seeking Treatment in China.

❓ Frequently Asked Questions

Last updated: July 1, 2026 | Author: China Hospitals Guide Editorial Team | Prices are estimates in USD equivalent. CAR-T availability, trial enrollment status, and pricing change frequently. Final cost and eligibility confirmed after in-person consultation at the treating center.